查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949817

雙胍類藥物全球市場報告（2026年）

Biguanides Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，雙胍類藥物市場持續擴張，預計將從2025年的51.1億美元成長到2026年的52.8億美元，複合年成長率為3.4%。過去幾年的成長可歸因於第2型糖尿病盛行率的上升、人們對代謝性疾病認知的提高、非專利雙胍類藥物的供應增加、口服降血糖藥的普及以及肝臟標靶治療方法的進步。

預計未來幾年雙胍類藥物市場將穩定成長，到2030年市場規模將達到59.7億美元，複合年成長率（CAGR）為3.1%。預測期內的成長要素包括：對個人化醫療的需求不斷成長、遠端醫療在糖尿病照護中的應用、卵巢症候群（PCOS）發病率的上升、聯合治療的研發以及政府促進慢性病管理的舉措。預測期內的主要趨勢包括：個人化糖尿病管理方案、聯合治療的研發、適應症範圍擴大至第2型糖尿病以外、居家醫療和遠端患者監護以及價格合理的非專利雙胍類藥物。

糖尿病盛行率的不斷上升預計將推動雙胍類藥物市場的擴張。糖尿病是一種慢性代謝性疾病，其特徵是由於胰島素分泌不足或胰島素作用受損而導致的高血糖。糖尿病患者數量的快速成長歸因於生活方式的改變、人口老化以及診斷技術進步帶來的公眾意識的提高。雙胍類藥物可透過提高胰島素敏感性、抑制肝臟葡萄糖生成以及幫助降低第2型糖尿病患者的血糖值，從而有助於糖尿病的治療。例如，根據英國政府機構－健康改善和消除不平等辦公室（OHID）發布的數據，截至2024年3月，完成全部八項建議護理步驟的1型糖尿病患者比例較2022年3月至2023年3月成長了22%，2型糖尿病患者的比例成長了21%。此外，達到糖化血紅素（HbA1c）目標水準的患者比例也達到了創紀錄的37.9%。因此，糖尿病盛行率的不斷上升正在推動雙胍類藥物市場的成長。

雙胍類藥物市場的主要企業正優先開發創新解決方案，例如緩釋雙胍類製劑，旨在提高患者依從性、最佳化血糖控制並減少消化器官系統副作用。緩釋雙胍類製劑旨在隨著時間的推移逐漸釋放活性成分，從而穩定血中濃度、提高耐受性並增強糖尿病管理的長期依從性。例如，2023年8月，印度食品藥物管理局瑞迪博士實驗室（Dr. Reddy's Laboratories）推出了沙格列汀和鹽酸二甲雙胍的緩釋片。本產品是美國FDA核准的KOMBIGLYZE XR（DPP-4抑制劑沙格列汀和二甲雙胍的複方製劑）的學名藥替代品。它為第2型糖尿病成人患者提供了一種便捷的每日一次給藥選擇，可與飲食和運動相結合，輔助血糖控制。其緩釋機制也有助於提高患者的依從性。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球雙胍類藥物市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 數位化、雲端運算、巨量資料、網路安全
    • 永續性、氣候技術和循環經濟
    • 人工智慧（AI）和自主人工智慧
    • 物聯網、智慧基礎設施和互聯生態系統
  • 主要趨勢
    • 個人化糖尿病管理解決方案
    • 聯合治療研發
    • 將適應症擴展到第 2 型糖尿病以外
    • 居家醫療和遠端患者監護
    • 經濟實惠的通用非專利藥物

第5章 終端用戶產業市場分析

  • 醫院
  • 診所
  • 零售藥房
  • 網路藥房
  • 糖尿病護理中心

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球雙胍類藥物市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 全球雙胍類藥物市場規模、對比及成長率分析
  • 全球雙胍類藥物市場表現：規模與成長，2020-2025年
  • 全球雙胍類藥物市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場總量（TAM）

第9章 市場細分

  • 按類型
  • 二甲雙胍、苯乙雙胍和其他類型
  • 按劑型
  • 錠劑，口服液
  • 配方
  • 速釋、緩釋
  • 透過分銷管道
  • 醫院藥局、零售藥局、網路藥局
  • 按類型細分：二甲雙胍
  • 速釋二甲雙胍，緩釋二甲雙胍
  • 按類型細分：苯乙雙胍
  • 鹽酸苯乙雙胍
  • 按類型細分：其他類型
  • 二甲雙胍和丁福明組合藥物

第10章 區域與國家分析

  • 全球雙胍類藥物市場：依地區、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測
  • 全球雙胍類藥物市場：按國家/地區分類，實際數據和預測數據，2020-2025年、2025-2030年預測數據、2035年預測數據

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 雙胍類藥物市場：競爭格局及市場佔有率（2024年）
  • 雙胍類藥物市場：公司估值矩陣
  • 雙胍類藥物市場：公司概況
    • Pfizer Inc.
    • Sanofi-Aventis LLC
    • Viatris Inc.
    • Aurobindo Pharma Ltd.
    • Cipla Ltd

第37章：其他領先和創新企業

  • Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 雙胍類藥物市場展望 2030：提供新機會的國家
  • 雙胍類藥物市場展望 2030：新興細分市場機會
  • 雙胍類藥物市場2030年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: PH5MBIGU01_G26Q1

Biguanides are a class of drugs mainly prescribed for type 2 diabetes treatment. They reduce blood sugar by decreasing hepatic glucose production and enhancing insulin sensitivity. These drugs also manage polycystic ovary syndrome (PCOS) and various metabolic conditions.

The primary biguanides include metformin, phenformin, and several others. Metformin stands out as a commonly prescribed biguanide drug for managing type 2 diabetes by reducing blood glucose levels. It comes in multiple dosage forms, such as tablets and oral solutions, available in options like immediate-release and extended-release, and is distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have affected the biguanides market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), leading to higher production costs and potential delays in supply chains. Regions like Asia-Pacific, which are major manufacturing hubs for biguanides, are most impacted, particularly for metformin and extended-release formulations. Hospital and retail pharmacy segments may face temporary price increases, while local manufacturers might benefit from protective measures, encouraging domestic production and reducing dependency on imports. Overall, the tariffs have a mixed impact, creating challenges in cost management but potential incentives for local manufacturing.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $5.11 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, rising awareness of metabolic disorders, growth in generic biguanides availability, adoption of oral antidiabetic medications, advancements in liver-targeted therapies.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.97 billion in 2030 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, expansion of telemedicine for diabetes care, rising incidence of pcOS, development of combination therapies, government initiatives promoting chronic disease management. Major trends in the forecast period include personalized diabetes management solutions, combination therapy development, expanded indications beyond type 2 diabetes, home healthcare & remote patient monitoring, cost-effective generic biguanides.

The increasing prevalence of diabetes is anticipated to drive expansion in the biguanides market. Diabetes represents a chronic metabolic condition marked by high blood glucose levels resulting from inadequate insulin production or ineffective insulin action. This surge in diabetes stems from shifts in lifestyle, an aging population, and greater awareness through diagnostics. Biguanides aid in managing diabetes by enhancing insulin sensitivity, curbing glucose output from the liver, and assisting in blood sugar reduction for those with type 2 diabetes. For instance, in March 2024, data from the Office for Health Improvement & Disparities (OHID), a UK government body, showed that from March 2022 to March 2023, the share of type 1 diabetes patients completing all eight recommended care processes rose by 22%, with a 21% increase for type 2 diabetes, and the percentage meeting target HbA1c levels hit 37.9%-the highest on record. Thus, the growing incidence of diabetes is fueling biguanides market growth.

Major companies in the biguanide market are prioritizing the development of innovative solutions like extended-release biguanide formulations to boost patient compliance, optimize glycemic control, and reduce gastrointestinal side effects. Extended-release biguanide formulations are medications engineered to release their active ingredient slowly over time, ensuring steady blood levels, better tolerability, and stronger long-term adherence for people managing diabetes. For example, in August 2023, Dr. Reddy's Laboratories, an India-based biotech firm, introduced saxagliptin and metformin hydrochloride extended-release tablets-a USFDA-approved generic equivalent of KOMBIGLYZE XR that pairs saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide-providing adults with type 2 diabetes a convenient once-daily option that aids glycemic control alongside diet and exercise, while its extended-release mechanism promotes greater adherence.

In August 2023, Lupin, an India-based biopharmaceutical firm, purchased the diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This deal bolsters Lupin's standing in the anti-diabetes market by broadening its lineup with proven oral antidiabetic treatments. It also boosts the company's capacity to enhance patient access to vital diabetes drugs and solidifies its rivalry in the metabolic disorders sector. Boehringer Ingelheim, a Germany-based biopharmaceutical firm, focuses on researching, developing, and manufacturing therapies for human and veterinary use.

Major companies operating in the biguanides market are Pfizer Inc., Sanofi-Aventis LLC, Viatris Inc., Aurobindo Pharma Ltd., Cipla Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories

Asia-Pacific was the largest region in the biguanides market in 2025. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Metformin; Phenformin; Other Types
  • 2) By Dosage Form: Tablets; Oral Solutions
  • 3) By Formulation: Immediate Release; Extended Release
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
  • 2) By Phenformin: Phenformin Hydrochloride
  • 3) By Other Types: Buformin; Metformin Combinations
  • Companies Mentioned: Pfizer Inc.; Sanofi-Aventis LLC; Viatris Inc.; Aurobindo Pharma Ltd.; Cipla Ltd; Dr. Reddy's Laboratories; Lupin Limited; Zydus Lifesciences Limited; Torrent Pharmaceuticals Limited; Intas Pharmaceuticals Ltd.; Apotex Inc; Sun Pharmaceutical Industries Ltd.; Glenmark Pharmaceuticals Ltd.; Mylan Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Alkem Laboratories Ltd.; Panacea Biotech Ltd.; Wanbury Ltd; USV Private Limited; Abbott Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Biguanides Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Biguanides Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Biguanides Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Biguanides Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Sustainability, Climate Tech & Circular Economy
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Personalized Diabetes Management Solutions
    • 4.2.2 Combination Therapy Development
    • 4.2.3 Expanded Indications Beyond Type 2 Diabetes
    • 4.2.4 Home Healthcare & Remote Patient Monitoring
    • 4.2.5 Cost-Effective Generic Biguanides

5. Biguanides Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Clinics
  • 5.3 Retail Pharmacies
  • 5.4 Online Pharmacies
  • 5.5 Diabetes Care Centers

6. Biguanides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Biguanides Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Biguanides PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Biguanides Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Biguanides Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Biguanides Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Biguanides Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Biguanides Market Segmentation

  • 9.1. Global Biguanides Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Metformin, Phenformin, Other Types
  • 9.2. Global Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Tablets, Oral Solutions
  • 9.3. Global Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Immediate Release, Extended Release
  • 9.4. Global Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • 9.5. Global Biguanides Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Immediate-Release Metformin, Extended-Release Metformin
  • 9.6. Global Biguanides Market, Sub-Segmentation Of Phenformin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Phenformin Hydrochloride
  • 9.7. Global Biguanides Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Buformin, Metformin Combinations

10. Biguanides Market Regional And Country Analysis

  • 10.1. Global Biguanides Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Biguanides Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Biguanides Market

  • 11.1. Asia-Pacific Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Biguanides Market

  • 12.1. China Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Biguanides Market

  • 13.1. India Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Biguanides Market

  • 14.1. Japan Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Biguanides Market

  • 15.1. Australia Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Biguanides Market

  • 16.1. Indonesia Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Biguanides Market

  • 17.1. South Korea Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Biguanides Market

  • 18.1. Taiwan Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Biguanides Market

  • 19.1. South East Asia Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Biguanides Market

  • 20.1. Western Europe Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Biguanides Market

  • 21.1. UK Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Biguanides Market

  • 22.1. Germany Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Biguanides Market

  • 23.1. France Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Biguanides Market

  • 24.1. Italy Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Biguanides Market

  • 25.1. Spain Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Biguanides Market

  • 26.1. Eastern Europe Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Biguanides Market

  • 27.1. Russia Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Biguanides Market

  • 28.1. North America Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Biguanides Market

  • 29.1. USA Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Biguanides Market

  • 30.1. Canada Biguanides Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Biguanides Market

  • 31.1. South America Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Biguanides Market

  • 32.1. Brazil Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Biguanides Market

  • 33.1. Middle East Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Biguanides Market

  • 34.1. Africa Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Biguanides Market, Segmentation By Type, Segmentation By Dosage Form, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Biguanides Market Regulatory and Investment Landscape

36. Biguanides Market Competitive Landscape And Company Profiles

  • 36.1. Biguanides Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Biguanides Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Biguanides Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Cipla Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Biguanides Market Other Major And Innovative Companies

  • Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories

38. Global Biguanides Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Biguanides Market

40. Biguanides Market High Potential Countries, Segments and Strategies

  • 40.1 Biguanides Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Biguanides Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Biguanides Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer